Abstract 1094P
Background
NeoIT with anti-PD-1 (PD1) is now a standard of care for patients (pts) with resectable stage IIIB–D melanoma. Although pathological response is predictive of recurrence, this variable alone cannot accurately identify those pts who will recur, particularly non-responders. We sought to build a recurrence risk assessment tool based on pts demographics, disease characteristics, pathological and imaging data.
Methods
Pts with resectable stage IIIB–D melanoma treated with PD1-based neoIT were included. Pts demographics, disease characteristics, blood parameters, pathological and imaging data at baseline (BL) and post-treatment (post-Tx), and clinical outcomes were analysed. A penalised multivariable logistic regression model was built to predict recurrence and a tool (NeoRisk) predicting the likelihood of recurrence for individual patients was generated.
Results
164 pts who underwent surgery post PD1-based NeoIT and had at least 6 months of follow-up were included; training cohort (n=114; 16 recurrences, 14%) and validation cohort (n=50; 7 recurrences, 14%). After the analysis of >50 variables, the combination of 4 variables accurately predicted recurrence (training cohort, AUC=0.91; validation cohort, AUC=0.93): 1) % of viable tumour cells in the tumour bed post-Tx (AOR=2.55, p=0.0016); 2) density of tumour-infiltrating lymphocytes (TILs) post-Tx (absence, mild, moderate, marked; e.g. marked vs absence, OR=0.39, p=0.0115); 3) difference in the % of fibrosis from BL to post-Tx (OR=0.69, p=0.0531); and 4) % tumour change from BL by RECIST (OR=2.06, p=0.0043). NeoRisk can be used to predict recurrence for individual patients; for example, Patient A with 55% of viable tumour cells and mild TILs post-Tx, 0% and 2% of fibrosis at BL and post-Tx, respectively, and 13% increase of tumour size from BL, has a risk of recurrence of 82%; while Patient B, with the same % of viable tumour cells, but moderate TILs post-Tx, 0% and 35% of fibrosis at BL and post-Tx, respectively, and 12% decrease of tumour size from BL, has a lower risk of recurrence of 20%.
Conclusions
NeoRisk can accurately predict recurrence after NeoIT, which may help tailor adjuvant treatment and radiological surveillance interval based on the predicted risk of recurrence for individual patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Melanoma Institute Australia.
Funding
Has not received any funding.
Disclosure
I. Pires da Silva: Financial Interests, Personal, Invited Speaker: BMS, MSD, Roche, Novartis; Financial Interests, Personal, Other, Travel Support: BMS, Roche; Financial Interests, Personal, Advisory Board: MSD. R. Rawson: Financial Interests, Personal, Invited Speaker: MSD. M.S. Carlino: Financial Interests, Personal, Advisory Board, Consultant Advisor: MSD, BMS, Novartis, Amgen, Oncosec, Merck, Sanofi, Ideaya, Pierre Fabre, Eisai, Nektar, Regeneron. A.M. Menzies: Financial Interests, Personal, Advisory Board, advisory board: BMS, MSD, Novartis, Roche, Pierre Fabre, QBiotics. R.A. Scolyer: Financial Interests, Personal, Advisory Role: SkylineDx BV, IO Biotech ApS, MetaOptima Technology Inc, F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc, Bristol Myers Squibb, Myriad Genetics, GSK. G.V. Long: Financial Interests, Personal, Other, Consultant Advisor: Agenus Inc, Amgen Inc, Array Biopharma Inc, AstraZeneca UK Limited, Bayer Healthcare Pharmaceuticals, BioNTech SE, Boehringer Ingelheim Ingelheim International GmbH, Bristol Myers Squibb, Evaxion Biotech A/S, Hexal AG, Highlight Therapeutics S.L, IOBiotech, Immunocore Ireland Limited, Innovent Bioilogics USA Inc, Merck Sharp & Dohme, Novartis Pharma AG, PHMR Limited, Pierre Fabre, Regeneron Pharmaceuticals Inc, Scancell Limited, SkylineDX B.V; Non-Financial Interests, Principal Investigator, GL is PI on over 30 clinical trials: GL is PI on over 30 clinical trials. All other authors have declared no conflicts of interest.
Resources from the same session
1064P - Optimizing infusion rates of monoclonal antibodies to save time for oncology day care and patients
Presenter: Elisabeth Cornelia Suzanne de Boer
Session: Poster session 04
1065P - Dose dependent detrimental effect of baseline pantoprazole on clinical outcomes from first-line chemo-ICI regimens in patients with advanced stage NSCLC
Presenter: Leonardo Brunetti
Session: Poster session 04
1066P - Potential effects of olanzapine: Enhancing the immune response to PD-1/PD-L1 inhibitors
Presenter: yan ling Yi
Session: Poster session 04
Resources:
Abstract
1068P - Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate)
Presenter: Arielle Elkrief
Session: Poster session 04
1069TiP - A phase I/IIa dose escalation and expansion study of 23ME-01473, an anti-ULBP6/2/5 antibody, for patients with advanced solid malignancies
Presenter: Manish Sharma
Session: Poster session 04
1070TiP - A phase Ia/Ib dose-escalation/expansion study of NPX887 in subjects with solid tumor malignancies known to express HHLA2/B7-H7
Presenter: Haiying Cheng
Session: Poster session 04
1071TiP - Phase I study of the investigational CD228 x 4-1BB costimulatory antibody anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors
Presenter: Reinhard Dummer
Session: Poster session 04
1073TiP - A phase I/IIa first in-human phase I study of BI 1910, a monoclonal antibody agonistic to TNFR2, as a single agent and in combination with pembrolizumab in subjects with advanced solid tumors
Presenter: Tatiana Hernandez Guerrero
Session: Poster session 04